Quantum-Si Incorporated (QSI)
NASDAQ:QSI
Want to see QSI full AI Analyst Report?
Top Page
Quantum-Si
(NASDAQ:QSI)
Select Model
Select Model
Rating:49Neutral
Price Target:
$0.99
▼(-7.94% Downside)
Action:Reiterated
Date:05/22/26
The score is held down primarily by weak financial performance—minimal/declining revenue, large losses, and heavy ongoing cash burn—despite low leverage. Offsetting this, the latest earnings call was moderately positive due to strong cash runway guidance and tangible Proteus technical progress, while technicals are mixed and valuation support is limited given negative earnings and no dividend.
Positive Factors
Cash runway supporting operations
A cash balance of $190.4M with management guidance that it supports operations into 2028 materially reduces near-term financing pressure. This durable runway funds continued R&D, scale-up and early commercialization activities, increasing the odds of reaching commercial milestones without immediate dilution.
Negative Factors
Sustained high cash burn
Operating cash outflows near $90M–$95M per year are structurally large versus current revenue, steadily depleting assets absent meaningful top-line gains. Persistently negative free cash flow increases reliance on the balance sheet or financing, limiting flexibility for multi-year commercialization investments.
Read all positive and negative factors
Positive Factors
Negative Factors
Cash runway supporting operations
A cash balance of $190.4M with management guidance that it supports operations into 2028 materially reduces near-term financing pressure. This durable runway funds continued R&D, scale-up and early commercialization activities, increasing the odds of reaching commercial milestones without immediate dilution.
Read all positive factors
Quantum-Si Key Performance Indicators (KPIs)
Any
Revenue by Segment
Details revenue contributions from each business unit, highlighting which areas are most lucrative and where growth or decline is occurring.
Details revenue contributions from each business unit, highlighting which areas are most lucrative and where growth or decline is occurring.
Data provided by:
The Fly
The FlyQuantum-Si (QSI) vs. SPDR S&P 500 ETF (SPY)
Market Cap
$230.83M
Dividend YieldN/A
Average Volume (3M)6.58M
Price to Earnings (P/E)―
Beta (1Y)2.94
Revenue Growth-46.21%
EPS Growth23.81%
CountryUS
Employees149
SectorHealthcare
Sector Strength45
IndustryBiotechnology
Share Statistics
EPS (TTM)-0.51
Shares Outstanding197,822,660
10 Day Avg. Volume6,140,471
30 Day Avg. Volume6,575,021
Financial Highlights & Ratios
PEG Ratio0.08
Price to Book (P/B)0.99
Price to Sales (P/S)89.30
P/FCF Ratio-2.24
Enterprise Value/Market Cap0.77
Enterprise Value/Revenue95.68
Enterprise Value/Gross Profit239.14
Enterprise Value/Ebitda-1.94
Forecast
1Y Price Target
$2.50Price Target Upside133.64% Upside
Rating ConsensusModerate Buy
Number of Analyst Covering3
EPS Forecast (FY)-0.45
Revenue Forecast (FY)$1.03M
Quantum-Si Business Overview & Revenue Model
Company Description
Quantum-Si incorporated, a life sciences company, develops a single molecule detection platform for sample preparation and sequencing. It offers a proprietary single molecule detection platform for use in semiconductor industry to field proteomics...
How the Company Makes Money
Quantum-Si makes money primarily by selling (1) instrument systems for its protein sequencing platform and (2) recurring consumables and reagents used to run experiments on those instruments, with additional revenue potential from associated softw...
Quantum-Si Earnings Call Summary
Earnings Call Date:May 07, 2026
(Q1-2026)
| % Change Since: |
Next Earnings Date:Aug 10, 2026
Earnings Call Sentiment Positive
The call emphasized materially de-risking technical progress for the Proteus platform (successful integrated sequencing, increased amino acid detection, doubled read lengths, PTM strategy) and showed strong early customer engagement and a solid cash runway (~$190M) that supports development through launch. However, near-term revenue remains very small ($258k Q1; ~ $1M outlook for 2026), and the company faces significant R&D/commercialization spend and execution required to scale manufacturing and convert interest into sales. On balance, the advances on Proteus and financial runway are compelling positives, while near-term commercial and burn risks merit monitoring.Positive Updates
Successful Proteus Sequencing Milestone
Completed sequencing on fully integrated Proteus instruments, demonstrating end-to-end automation (reagent prep to data analysis); this milestone materially de-risks the new platform and confirms fundamental technology performance ahead of commercial launch.
Negative Updates
Very Low Near-Term Revenue
Revenue for Q1 2026 was only $258 thousand, driven primarily by consumable utilization and installed base; management expects 2026 revenue of approximately $1M, indicating limited near-term top-line growth as customers time purchases for Proteus availability.
Read all updates
Q1-2026 Updates
Positive
Negative
Successful Proteus Sequencing Milestone
Completed sequencing on fully integrated Proteus instruments, demonstrating end-to-end automation (reagent prep to data analysis); this milestone materially de-risks the new platform and confirms fundamental technology performance ahead of commercial launch.
Read all positive updates
Company Guidance
The company reiterated 2026 is a “transition year” and gave explicit financial guidance: total revenue of approximately $1.0 million, adjusted operating expenses of $98 million or less, and total cash usage of $93 million or less; as of 03/31/2026 it held $190.4 million in cash, cash equivalents and marketable securities, which management said supports operations into 2028 (roughly 1½ years after the estimated Proteus launch). Quarterly metrics included Q1 revenue of $258k, gross profit of $74k (29% gross margin), GAAP operating expenses of $24.1M (vs. $25.6M PY) and adjusted operating expenses of $21.4M (vs. $22.9M PY), and dividend/interest income of $1.9M (vs. $2.5M PY). Operational guidance and cadence: near-term revenue driven by consumable utilization, modest new capital placements and Platinum placements with embedded Proteus upgrade credits; management expects to complete manufacturing scale-up and early-access deployments (a “handful” of sites by summer), to offer broader sample evaluations as internal Proteus instruments increase, and to achieve product milestones (17 amino acids detected today, up from 15 in Dec‑2025, targeting 18 at delivery and all 20 during 2026 with a 2027 sequencing kit detecting all 20).Quantum-Si Financial Statement Overview
Summary
Income Statement
12
Very Negative
Balance Sheet
66
Positive
Cash Flow
18
Very Negative
| Breakdown | TTM | Dec 2025 | Dec 2024 | Dec 2023 | Dec 2022 | Dec 2021 |
|---|---|---|---|---|---|---|
Income Statement | ||||||
| Total Revenue | 1.85M | 2.44M | 3.06M | 1.08M | 0.00 | 0.00 |
| Gross Profit | 741.00K | 1.15M | 1.60M | 488.00K | 0.00 | 0.00 |
| EBITDA | -91.54M | -92.91M | -103.98M | -91.80M | -111.77M | -93.94M |
| Net Income | -103.82M | -101.34M | -101.01M | -95.96M | -132.44M | -94.99M |
Balance Sheet | ||||||
| Total Assets | 213.35M | 245.61M | 247.87M | 298.25M | 391.49M | 503.23M |
| Cash, Cash Equivalents and Short-Term Investments | 127.34M | 162.91M | 209.60M | 257.74M | 351.31M | 471.30M |
| Total Debt | 3.71M | 4.17M | 12.95M | 15.30M | 17.45M | 8.08M |
| Total Liabilities | 12.60M | 25.38M | 32.45M | 26.63M | 32.78M | 26.19M |
| Stockholders Equity | 200.74M | 220.23M | 215.42M | 271.62M | 358.71M | 477.03M |
Cash Flow | ||||||
| Free Cash Flow | -95.69M | -97.23M | -92.38M | -99.31M | -101.30M | -72.58M |
| Operating Cash Flow | -94.20M | -94.72M | -87.80M | -94.04M | -90.56M | -66.81M |
| Investing Cash Flow | 46.13M | -28.32M | -32.67M | 143.43M | 137.19M | -450.94M |
| Financing Cash Flow | 47.05M | 95.42M | 35.88M | 149.00K | 1.91M | 516.63M |
Quantum-Si Technical Analysis
Positive
1.07
Price Trends
0.90
Positive
0.99
Positive
1.24
Negative
Market Momentum
0.02
Negative
63.35
Neutral
88.66
Negative
Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For QSI, the sentiment is Positive. The current price of 1.07 is above the 20-day moving average (MA) of 0.94, above the 50-day MA of 0.90, and below the 200-day MA of 1.24, indicating a neutral trend. The MACD of 0.02 indicates Negative momentum. The RSI at 63.35 is Neutral, neither overbought nor oversold. The STOCH value of 88.66 is Negative, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Positive sentiment for QSI.
Quantum-Si Risk Analysis
Quantum-Si disclosed 69 risk factors in its most recent earnings report. Quantum-Si reported the most risks in the "Tech & Innovation" category.
Finance & Corporate - Financial and accounting risks. Risks related to the execution of corporate activity and strategy
Latest Risks Added 0 New Risks
Quantum-Si Peers Comparison
UnderperformOutperform
Sector (51)
Name | Overall Rating | Market Cap | P/E Ratio | ROE | Dividend Yield | Revenue Growth | EPS Growth |
|---|---|---|---|---|---|---|---|
58 Neutral | $685.15M | -9.27 | -33.07% | ― | ― | -20.34% | |
52 Neutral | $167.63M | -1.37 | -80.56% | ― | ― | 59.42% | |
51 Neutral | $7.86B | -0.30 | -43.30% | 2.27% | 22.53% | -2.21% | |
49 Neutral | $230.83M | -1.93 | -47.35% | ― | -46.21% | 23.81% | |
46 Neutral | $247.77M | -4.18 | 85.78% | ― | 20.08% | 14.06% | |
46 Neutral | $98.42M | -1.40 | -26.58% | ― | -1.44% | 11.50% | |
45 Neutral | $3.50B | -6.71 | -34.48% | ― | ― | -49.51% |
* Healthcare Sector Average
QSI
Quantum-Si
1.13
-0.65
-36.52%
FHTX
Foghorn Therapeutics
4.27
-0.03
-0.70%
SEER
Seer
1.89
-0.10
-5.03%
DSGN
Design Therapeutics
11.10
7.10
177.50%
ERAS
Erasca
12.47
11.37
1033.64%
TNYA
Tenaya Therapeutics
0.79
0.35
79.59%
Quantum-Si Corporate Events
Executive/Board ChangesShareholder Meetings
Quantum-Si Shareholders Back Leadership, Auditor and Pay Plans
Positive
May 15, 2026
On May 15, 2026, Quantum-Si held its Annual Meeting, with approximately 84.59% of the total voting power of its Class A and Class B common stock represented, establishing a quorum. Shareholders reelected all listed director nominees to serve until...
Glossary
BuyA stock rated as a "Buy" is expected to perform better than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock is likely to deliver higher returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
HoldA stock rated as a "Hold" is expected to perform in line with the overall market or a specific benchmark. This rating indicates that the stock is neither particularly compelling nor unfavorable for investment. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
SellA stock rated as a "Sell" is expected to perform worse than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock may deliver lower returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
Disclaimer
This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.